Retrieve available abstracts of 40 articles: HTML format
Single Articles
May 2025
SPINELLI I, Ianiro G Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition?
Authors' Reply.
Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70204. PubMed
CRISTOFORI F, Dargenio VN, Francavilla R Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition?
Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70179. PubMed
KAHRILAS PJ, Keefer L, Yadlapati R, Anastasiou F, et al Review Article: Individualised Management of Reflux-Like Symptoms-Strategies
Beyond Acid Suppression.
Aliment Pharmacol Ther. 2025;61:1437-1446. PubMedAbstract available
April 2025
SPINELLI I, Ianiro G Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter
pylori and Eosinophilic Oesophagitis. Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70135. PubMed
RAHMAN H Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter
pylori and Eosinophilic Oesophagitis.
Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70122. PubMed
SHARMA P, Vaezi M, Unge P, Andersson K, et al Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel
Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of
Erosive Oesophagitis.
Aliment Pharmacol Ther. 2025 Apr 4. doi: 10.1111/apt.70109. PubMedAbstract available
March 2025
SPINELLI I, Ianiro G Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects
of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply.
Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70099. PubMed
EMANUELE E, Minoretti P Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects
of Helicobacter pylori Against Eosinophilic Oesophagitis.
Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70075. PubMed
February 2025
SPINELLI I, Porcari S, Esposito C, Fusco W, et al Meta-Analysis: Inverse Association Between Helicobacter pylori Infection and
Eosinophilic Oesophagitis.
Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70042. PubMedAbstract available
MIYAHARA S, Yamashina T, Ohyama T, Banno M, et al Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype
Compared With Empirical Proton Pump Inhibitor.
Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70011. PubMed
CHUAH KH, Mahadeva S Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype
Compared With Empirical Proton Pump Inhibitor: Authors' Reply.
Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70025. PubMed
January 2025
FISCHMAN M, Elias A, Klein A, Cohen Y, et al Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30-Day Mortality
From Acute Pancreatitis.
Aliment Pharmacol Ther. 2025 Jan 31. doi: 10.1111/apt.18523. PubMedAbstract available
TAYLOR S, Chen L, Dutt K, Boyapati R, et al Blood Group B May Reduce Risk of Rebleeding in Patients With Upper
Gastrointestinal Haemorrhage due to Peptic Ulcer Disease.
Aliment Pharmacol Ther. 2025 Jan 9. doi: 10.1111/apt.18485. PubMedAbstract available
December 2024
ARMSTRONG D, Hungin AP, Kahrilas PJ, Sifrim D, et al Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump
Inhibitor Therapy: Evidence-Based Consensus Statements.
Aliment Pharmacol Ther. 2024 Dec 30. doi: 10.1111/apt.18420. PubMedAbstract available
HOWDEN CW, Katz P, DeVault KR, Metz DC, et al Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal
Reflux Disease or Erosive Oesophagitis.
Aliment Pharmacol Ther. 2024 Dec 25. doi: 10.1111/apt.18458. PubMedAbstract available
CHUAH KH, Loo QY, Hian WX, Khoo XH, et al Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared
With Empirical Proton Pump Inhibitor.
Aliment Pharmacol Ther. 2024 Dec 2. doi: 10.1111/apt.18418. PubMedAbstract available
September 2024
IDALSOAGA F, Diaz LA, Ayares G, Cabrera D, et al Letter: Potential impact of Helicobacter pylori infection on oesophageal
disorders in chronic liver disease-Authors' reply.
Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18246. PubMed
KOUNTOURAS J, Vardaka E, Zavos C, Chatzopoulos D, et al Letter: Potential impact of Helicobacter pylori infection on oesophageal
disorders in chronic liver disease.
Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18220. PubMed
July 2024
KOUNTOURAS J, Polyzos SA, Kazakos E, Zavos C, et al Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin
resistance and lipotoxicity in the pathogenesis of MAFLD and MASH.
Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18124. PubMed
BANSAL SK, Bansal MB 'Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin
resistance and lipotoxicity in the pathogenesis of MAFLD and MASH-Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18182. PubMed
BAGER P, Dahlerup JF Letter: Post-endoscopic management after upper gastrointestinal
bleeding-Replenishment of iron loss.
Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18050. PubMed
WANG Y, Pan Y Letter: Reflections on the role of over-the-scope clips in high-risk upper
gastrointestinal bleeding.
Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18145. PubMed
LYU C, Yang D, Xu H, He K, et al Letter: Reflections on the role of over-the-scope clips in high-risk upper
gastrointestinal bleeding-Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18173. PubMed
YOON JS, Lee JH Letter: Risks of proton pump inhibitor treatment in cirrhotic patients-Authors'
reply.
Aliment Pharmacol Ther. 2024 Jul 12. doi: 10.1111/apt.18167. PubMed
SCHEINER B, Dominik N, Mandorfer M Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor
and plasminogen activator inhibitor-1 activity levels for outcome prediction of
advanced chronic liver disease: Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18144. PubMed
KOUNTOURAS J, Polyzos SA, Kazakos E, Papanikolaou IS, et al Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor
and plasminogen activator inhibitor-1 activity levels for outcome prediction of
advanced chronic liver disease.
Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18066. PubMed
April 2024
WANG J, Wen F, Zhao J Letter: Risks of proton pump inhibitor treatment in cirrhotic patients.
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17954. PubMed
March 2024
SHUNG DL, Laine L Review article: Upper gastrointestinal bleeding - review of current evidence and
implications for management.
Aliment Pharmacol Ther. 2024 Mar 22. doi: 10.1111/apt.17949. PubMedAbstract available
KRAUSE AJ, Yadlapati R Review article: Diagnosis and management of laryngopharyngeal reflux.
Aliment Pharmacol Ther. 2024;59:616-631. PubMedAbstract available
February 2024
YOON JS, Hong JH, Park SY, Kim SU, et al High-dose proton pump inhibitor treatment is associated with a higher mortality
in cirrhotic patients: A multicentre study.
Aliment Pharmacol Ther. 2024 Feb 22. doi: 10.1111/apt.17909. PubMedAbstract available
LON N, Engel S, Damholt A, Mortensen B, et al Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage:
A randomised, double blind, placebo-controlled crossover trial.
Aliment Pharmacol Ther. 2024;59:341-349. PubMedAbstract available
August 2023
GONG EJ, Jung HK, Lee B, Hong J, et al Proton pump inhibitor use and the risk of metachronous gastric cancer after H.
pylori eradication in patients who underwent endoscopic resection for gastric
neoplasms: A population-based cohort study.
Aliment Pharmacol Ther. 2023 Aug 17. doi: 10.1111/apt.17676. PubMedAbstract available
July 2023
WAUTERS L, Harris PR, Walker MM, Serrano CA, et al Letter: childhood recurrent abdominal pain is associated with increased duodenal
eosinophilia independent of Helicobacter pylori infection.
Aliment Pharmacol Ther. 2023;58:134-136. PubMed
May 2023
PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al Letter: Potassium-competitive acid blockers may increase the risk of gastric
cancer after Helicobacter pylori eradication-a retrospective multicentre-cohort
analysis. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1199-1200. PubMed
KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al Letter: higher severe outcomes among Helicobacter pylori-related lean patients
with non-alcoholic fatty liver disease and metabolic comorbidities.
Aliment Pharmacol Ther. 2023;57:1186-1187. PubMed
ARAI J, Hayakawa Y, Niikura R, Ihara S, et al Letter: Potassium-competitive acid blockers may increase the risk of gastric
cancer after Helicobacter pylori eradication a retrospective multicentre-cohort
analysis.
Aliment Pharmacol Ther. 2023;57:1196-1198. PubMed
April 2023
HOWDEN CW, Shah S, Pendse SN, Offman E, et al Physiologically based pharmacokinetic modelling to predict intragastric rifabutin
concentrations in the treatment of Helicobacter pylori infection.
Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17526. PubMedAbstract available
SCARPIGNATO C, Howden CW, Leifke E, Mulford DJ, et al A translational pharmacokinetic/pharmacodynamic approach supports optimal
vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
Aliment Pharmacol Ther. 2023 Apr 17. doi: 10.1111/apt.17510. PubMedAbstract available
March 2023
TAILLIEU E, De Witte C, De Schepper H, Van Moerkercke W, et al Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter
species in gastric disease.
Aliment Pharmacol Ther. 2023 Mar 28. doi: 10.1111/apt.17488. PubMedAbstract available